No Data
No Data
No Data
No Data
No Data
Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024
BRIDGEWATER, N.J., April 25, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases,
PR NewswireApr 25 20:00
Insmed Initiated at Buy by Truist Securities
Insmed Initiated at Buy by Truist Securities
Dow JonesApr 23 18:50
Insmed (INSM.US) was first covered by Truist Securities, which gave it a buy rating, with a target price of $48.00.
Insmed (INSM.US) was first covered by Truist Securities, which gave it a buy rating, with a target price of $48.00.
Zhitong FinanceApr 23 18:41
Analysts Conflicted on These Healthcare Names: Cartesian Therapeutics (RNAC), Insmed (INSM) and BioNTech SE (BNTX)
TipRanksApr 23 18:40
Truist Securities Initiates Coverage On Insmed With Buy Rating, Announces Price Target of $48
Truist Securities analyst Nicole Germino initiates coverage on Insmed with a Buy rating and announces Price Target of $48.
Analyst UpgradesApr 23 18:40
Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and UnitedHealth (UNH)
TipRanksApr 17 01:20
No Data
No Data